

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**VOLUNTARY ANNOUNCEMENT
DFVISION 3D ELECTRONIC LAPAROSCOPE OBTAINED
THE EU CE MARK**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company is pleased to announce that the DFVision 3D Electronic Laparoscope (the “**DFVision**”), which is independently developed by the Group, has successfully approved by the British Standards Institution (BSI) and obtained the EU CE mark.

ABOUT DFVISION

DFVision is a 3D electronic laparoscope independently developed by the Group, which can be used in intraoperative exploration and imaging for laparoscopic surgery to make observation, diagnosis, photography or treatment of abdominal and thoracic organs, among others. Through the application of high-resolution imaging objective lens and electronic lens structure, it presents full HD two-way images, provides the operator with the 3D sense of surgical field of vision and natural depth of field. It can also meet the anatomical demand of clinical high-definition at high 3D level, being of great significance in surgery for precise dissection, suturing, and knotting, which is able to shorten surgery time, reduce surgery errors, improve surgery quality and increase surgery efficiency, breaking the limitation of traditional two-dimensional laparoscopic surgery, and is suitable for urology, general surgery, thoracic surgery, gynecology and other multi-department surgery.

IMPACT ON THE COMPANY

Obtaining the EU CE mark for the DFVision is a recognition of such product's safety and a solid foundation for its subsequent clinical application and international market entry. This will also help the Group serve a wider range of doctor-patient groups, maximize the value of domestic advanced medical devices in clinical translation, and realize the belief of “make surgery easier, safer and less invasive”.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 29 June 2023

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.